BioTuesdays

Category - News

Proteon Therapeutics
Markets

Maxim starts Proteon Therapeutics at buy; PT $5

Maxim Group launched coverage of Proteon Therapeutics (NASDAQ:PRTO) with a “buy” rating and a price target of $5. The stock closed at $1.71 on Oct. 29. The company’s vonapanitase drug candidate is being evaluated in its...

October 30, 2018
Celyad Logo
Markets

WB starts Celyad at OP; fair market value $53

William Blair launched coverage of Celyad S.A. (NASDAQ:CYAD) with an “outperform” rating and a fair value estimate of $53. The stock closed at $23.58 on Oct.29. Celyad’s lead candidate, CYAD-01, is an autologous...

October 30, 2018
ADMA Biologics Logo
Markets

HCW starts ADMA Biologics at buy; PT $17

H.C. Wainwright initiated coverage of ADMA Biologics (NASDAQ:ADMA) with a “buy” rating and $17 price target. The stock closed at $5.03 on Oct. 29. Since its IPO in 2013, the company’s focus has been on bringing a...

October 30, 2018
Inspire Medical
Markets

Leerink starts Inspire Medical at OP; PT $57

Leerink launched coverage of Inspire Medical Systems (NYSE:INSP) with an “outperform” rating and $57 price target. The stock closed at $40 on Oct. 26. “We see Inspire as a sustainable ultra high-growth/gross margin...

October 29, 2018
IRIDEX
Markets

Stifel starts IRIDEX at buy; PT $9

Stifel initiated coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and price target of $9. The stock closed at $5.40 on Oct. 25. IRIDEX is a leader in developing, manufacturing, and marketing laser-based medical...

October 26, 2018
Athenex
Markets

Ladenburg starts Athenex at buy; PT $27

Ladenburg Thalmann launched coverage of Athenex (NASDAQ:ATNX) with a “buy” rating and $27 price target. The stock closed at $12.37 on Oct. 24. Athenex is focused on the development and commercialization of novel...

October 25, 2018